Mikkael A. Sekeres, MD, MS

Mikkael A. Sekeres, MD, discusses how data from the phase 3 QuANTUM-First trial may advance the treatment field for patients with newly diagnosed FLT3-ITD–positive acute myeloid leukemia.

The myelodysplastic syndromes (MDS) are a heterogeneous spectrum of clonal hematopoietic diseases characterized by bone marrow hypercellularity, dysplasia of cellular elements, and consequent inadequate hematopoiesis, with resultant peripheral blood cytopenias.